Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

MLA

Friedlander, M., et al. Patient-Centred Outcomes and Effect of Disease Progression on Health Status in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Receiving Maintenance Olaparib or Placebo (SOLO1): A Randomised, Phase 3 Trial. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1308939335&authtype=sso&custid=ns315887.

APA

Friedlander, M., Moore, K., Colombo, N., Scambia, G., Kim, B., Oaknin, A., Lisyanskaya, A., Sonke, G., Gourley, C., Banerjee, S., Oza, A., Gonzalez-Martin, A., Aghajanian, C., Bradley, W., Liu, J., Mathews, C., Selle, F., Lortholary, A., Lowe, E., … DiSilvestro P. (2021). Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

Chicago

Friedlander, M, K Moore, N Colombo, G Scambia, B Kim, A Oaknin, A Lisyanskaya, et al. 2021. “Patient-Centred Outcomes and Effect of Disease Progression on Health Status in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Receiving Maintenance Olaparib or Placebo (SOLO1): A Randomised, Phase 3 Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1308939335&authtype=sso&custid=ns315887.